BPC-157 Oral Protocol Guide
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice that demonstrates remarkable stability in the GI tract. While injectable BPC-157 is commonly used for systemic musculoskeletal repair, oral administration specifically targets gastrointestinal healing including gastric ulcer repair, gut lining integrity, and inflammatory bowel support. The arginine salt form (BPC-157 Arginate) offers enhanced stability in gastric acid. This protocol covers oral capsule dosing at 250-500mcg twice daily, form selection, GI healing timelines, and stacking with gut-supportive compounds.
Protocol Overview
- Compound
- BPC-157 Oral (Body Protection Compound-157)
- Category
- GI Repair / Tissue Healing Peptide
- Mechanism
- Upregulates growth factor expression (EGF, VEGF), promotes angiogenesis in GI mucosa, modulates NO system, protects endothelium, accelerates mucosal healing
- Sequence
- 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)
- Preferred Form
- Arginine salt (Arginate) for acid stability
- Route
- Oral (capsule)
- Frequency
- 2x daily on empty stomach
- Cycle Length
- 4-8 weeks
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard GI Repair | 250 mcg | 2x daily (AM + PM, fasted) | Oral | 4-8 weeks |
| Intensive GI Protocol | 500 mcg | 2x daily (AM + PM, fasted) | Oral | 4-8 weeks |
| Maintenance | 250 mcg | 1x daily (AM, fasted) | Oral | Ongoing |
Key principle: Take on an empty stomach for direct contact with the gastric and intestinal mucosa. The arginine salt form is preferred for oral use due to superior stability in low pH environments.
Administration Guide
Oral Administration
- Form: Capsules (arginine salt preferred)
- Timing: 30 min before meals, empty stomach
- Morning dose: Upon waking, before breakfast
- Evening dose: 2+ hours after last meal
- Water: Take with minimal water
Form Comparison
- Arginine salt: Best for oral use; acid stable
- Acetate salt: Better for injection; less acid stable
- Sodium salt: Alternative oral form; moderate stability
- Storage: Room temperature, dry, sealed
- Shelf life: 12-24 months (capsule form)
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Mild nausea (rare, usually resolves in days)
- Slight changes in bowel habits initially
- Minimal systemic side effects due to local GI action
- Extremely well tolerated in research
BPC-157 has demonstrated an excellent safety profile across numerous preclinical studies with no reported organ toxicity even at high doses.
Precautions
- Limited human clinical trial data for oral form
- May interact with medications metabolized in the GI tract
- Monitor for any changes in existing GI medication needs
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- BPC-157 Injectable: Systemic + local GI coverage
- KPV: Anti-inflammatory peptide for IBD support
- TB-500: Systemic tissue repair complement
- L-Glutamine: Gut lining amino acid support
- Zinc Carnosine: Additional gastric mucosal protection
Popular Stacks
- GI Repair Stack: BPC-157 Oral 500mcg 2x/day + KPV topical
- Full BPC Stack: BPC-157 Oral + BPC-157 SubQ 250mcg/day
- Gut Healing: BPC-157 Oral + L-Glutamine 5g/day
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| GI Assessment | Calprotectin, lactulose/mannitol ratio | Baseline, Week 8 |
| Inflammation | CRP, ESR | Baseline, Week 4, Week 8 |
| Liver Function | ALT, AST, GGT | Baseline, Week 8 |
| Metabolic | CMP, CBC | Baseline |
Fecal calprotectin provides the most direct measure of GI inflammation reduction. Lactulose/mannitol testing assesses intestinal permeability improvements.
Related Tools & Resources
